Literature DB >> 19265012

The challenge of finding a cure for HIV infection.

Douglas D Richman1, David M Margolis, Martin Delaney, Warner C Greene, Daria Hazuda, Roger J Pomerantz.   

Abstract

Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4+ lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265012     DOI: 10.1126/science.1165706

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  439 in total

Review 1.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

2.  Moving ahead an HIV vaccine: use both arms to beat HIV.

Authors:  Bruce D Walker; Rafi Ahmed; Stanley Plotkin
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

3.  Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.

Authors:  Jana Blazkova; Tae-Wook Chun; Bietel W Belay; Danielle Murray; J Shawn Justement; Emily K Funk; Amy Nelson; Claire W Hallahan; Susan Moir; Paul A Wender; Anthony S Fauci
Journal:  J Infect Dis       Date:  2012-06-25       Impact factor: 5.226

4.  The outlook for a cure.

Authors:  Virginia Hughes
Journal:  Nature       Date:  2010-07-15       Impact factor: 49.962

5.  Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells.

Authors:  Hao Yin; Yuhao Zhang; Xin Zhou; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2010-12-23       Impact factor: 2.316

6.  Negative elongation factor (NELF) coordinates RNA polymerase II pausing, premature termination, and chromatin remodeling to regulate HIV transcription.

Authors:  Malini Natarajan; Gillian M Schiralli Lester; Chanhyo Lee; Anamika Missra; Gregory A Wasserman; Martin Steffen; David S Gilmour; Andrew J Henderson
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 7.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

8.  HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals.

Authors:  Fredrick H Omondi; Sandali Chandrarathna; Shariq Mujib; Chanson J Brumme; Steven W Jin; Hanwei Sudderuddin; Rachel L Miller; Asa Rahimi; Oliver Laeyendecker; Phil Bonner; Feng Yun Yue; Erika Benko; Colin M Kovacs; Mark A Brockman; Mario Ostrowski; Zabrina L Brumme
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

9.  A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption.

Authors:  Rui Wang; Ante Bing; Cathy Wang; Yuchen Hu; Ronald J Bosch; Victor DeGruttola
Journal:  Stat Med       Date:  2020-04-15       Impact factor: 2.373

10.  No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.

Authors:  Rajesh T Gandhi; Ronald J Bosch; Evgenia Aga; Mary Albrecht; Lisa M Demeter; Carrie Dykes; Barbara Bastow; Michael Para; Jun Lai; Robert F Siliciano; Janet D Siliciano; Joseph J Eron
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.